Fig. 6From: Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancerThe estimation of prognosis model in immunotherapy response. A Correlation of riskScore with immune checkpoints. B PD1 expression in high and low risk groups. C CTLA4 expression in high and low risk groups. D-F PD1 and CTLA4 immunotherapy in TCIA. E CTLA4 immunotherapy in TCIA. F PD1 immunotherapy in TCIA. G Relationship between high and low risk groups and TIDE scores. H Relationship between high and low risk groups and exclusion. I Relationship between high and low risk groups and DysfunctionBack to article page